Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Ganetespib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Synta Pharmaceuticals
- 17 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Jul 2017.
- 17 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.
- 31 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.